RT Journal Article
SR Electronic
T1 REVERSIBLE PRE-CAPILLARY PULMONARY HYPERTENSION DUE TO DASATINIB
JF Respiratory Care
FD American Association for Respiratory Care
SP respcare.02692
DO 10.4187/respcare.02692
A1 Herminia L. Buchelli Ramirez
A1 Celso M. Alvarez Alvarez
A1 José J. Rodríguez Reguero
A1 Marta M. García Clemente
A1 Pere Casan Clará
YR 2013
UL http://rc.rcjournal.com/content/early/2013/10/22/respcare.02692.abstract
AB Pulmonary arterial hypertension (PAH) and secondary pleural effusion have been reported in association with long-term therapy with the multi tyrosine kinase inhibitor dasatinib, approved for the treatment of chronic myeloid leukemia (CML). We present the case of a 50-year-old man diagnosed with CML in August 2003, who developed PAH after more than four years of treatment with dasatinib. The complete remission of PAH following dasatinib discontinuation suggests an etiological role of the drug in its development, although the administration of sildenafil may have played a therapeutic role.